Trophos
From Wikipedia, the free encyclopedia
- Christopher Henderson
- Olivier Pourquie
- Jean-Louis Kraus
- Antoine Beret
- Michel Delaage
| Company type | Privately held company |
|---|---|
| Industry | research and development in biotechnology |
| Founded | Marseille, France (1999) |
| Founder |
|
| Defunct | 2015 |
| Fate | Acquired by Hoffmann-La Roche |
| Headquarters | France |
Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.[citation needed]
Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622),[1][2] a mitochondrial targeted compound developed to treat neurodegenerative diseases.[3][4]
In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments.[5][6] The deal was completed shortly afterwards.